| Literature DB >> 30260970 |
João Victor Rolim1, Jaquelina Sonoe Ota-Arakaki1, Eloara V M Ferreira1, Gabriela A M Figliolino1, Ivan Ivanaga1, Elaine Brito Vieira1, Angelo X C Fonseca1, Carolina M S Messina1, Camila Melo Costa1, J Alberto Neder1,2, Luiz Eduardo Nery1, Roberta Pulcheri Ramos1.
Abstract
Determination of potentially-reversible factors contributing to exertional dyspnea remains an unmet clinical need in chronic thromboembolic pulmonary hypertension (CTEPH). Therefore, we aimed to evaluate the influence of inspiratory muscle weakness (IMW) on exercise capacity and dyspnea during effort in patients with CTEPH. We performed a prospective cross-sectional study that included thirty-nine consecutive patients with CTEPH (48 ± 15 yrs, 61% female) confirmed by right heart catheterization that underwent an incremental cardiopulmonary exercise test, 6-minute walk test and maximum inspiratory pressure (MIP) measurement. MIP < 70%pred was found in 46% of patients. On a multiple linear regression analysis, MIP was independently associated with 6MWD and [Formula: see text]. Patients with MIP < 70% presented greater [Formula: see text] than those with MIP ≥ 70%. Additionally, they also presented stronger sensations of dyspnea throughout exercise, even when adjusted for ventilation. At rest and at different levels of exercise, mean inspiratory flow (VT/TI) was significantly higher in patients with MIP < 70%. In conclusion, IMW is associated with a rapid increase of dyspnea, higher inspiratory load and poor exercise capacity in patients with CTEPH.Entities:
Mesh:
Year: 2018 PMID: 30260970 PMCID: PMC6160017 DOI: 10.1371/journal.pone.0204072
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of patients with chronic thromboembolic pulmonary hypertension showing maximum inspiratory pressure < or ≥ 70% predicted.
| MIP < 70% | MIP ≥ 70% | ||
|---|---|---|---|
| Gender F [n (%)] | 12 (66) | 12 (57) | 0.39 |
| Age (years) | 49 ± 17 | 48 ± 14 | 0.93 |
| BMI (kg/m2) | 26.3 ± 5.6 | 29.6 ± 4.2 | 0.04 |
| 10 (55) | 13 (62) | 0.55 | |
| II | 6 (33) | 14 (67) | 0.039 |
| III/IV | 12 (67) | 7 (33) | |
| Sildenafil [n/(%)] | 2 (11) | 1 (5) | |
| Bosentan [n/(%) | 3 (17) | 3 (14) | |
| Riociguat [n/(%)] | 0 | 3 (14) | |
| Combination | 3(17) | 0 | |
| mPAP (mmHg) | 55 ± 12 | 50 ± 14 | 0.23 |
| PVR ( | 908 ± 300 | 799 ± 402 | 0.35 |
| RAP (mmHg) | 13 ± 4 | 11 ± 4 | 0.18 |
| Cardiac index (L/min/m2) | 2.3 ± 0.6 | 2.4 ± 0.8 | 0.40 |
| PaO2 (mmHg) | 62 ± 9 | 64 ± 11 | 0.689 |
| PaCO2 (mmHg) | 30 ± 5 | 31 ± 4 | 0.762 |
| SaO2 (mmHg) | 91 ± 3 | 92 ± 3 | 0.771 |
| MVV (L) | 92 ± 26 | 111 ± 22 | 0.013 |
| FEV1 (% pred) | 71 ± 12 | 83 ± 12 | 0.003 |
| FVC (% pred) | 76 ± 11 | 87 ± 13 | 0.005 |
| FEV1/FVC | 0.76 ± 0.07 | 0.73 ± 0.17 | 0.49 |
| DLCO (% pred) | 59 ± 17 | 64 ± 15 | 0.41 |
Data are expressed as the mean ± standard deviation or n (%), as indicated. F: female; BMI: body mass index; NYHA: New York Heart Association; mPAP: mean pulmonary artery pressure; RAP: right atrial pressure; PVR: pulmonary vascular resistance; PaO2: arterial partial pressure of oxygen; PaCO2: arterial partial pressure of carbon dioxide; SaO2: arterial oxyhemoglobin saturation; MVV: maximum voluntary ventilation; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity; DLCO: diffusion capacity for carbon monoxide (n = 31).
Six-minute walk test and cardiopulmonary exercise test responses in patients with chronic thromboembolic pulmonary hypertension showing maximum inspiratory pressure < or ≥ 70% predicted.
| MIP < 70% | MIP ≥ 70% | p value | |
|---|---|---|---|
| 6MWD (m) | 352 ± 116 | 438 ± 68 | 0.007 |
| 6MWD (% pred) | 65 ± 20 | 78 ± 11 | 0.013 |
| SpO2 (%) | 85 ± 8 | 87 ± 5 | 0.450 |
| WR PEAK (watts) | 47 ± 23 | 78 ± 27 | 0.001 |
| | 10.5 ± 2.4 | 13.1 ± 3.0 | 0.005 |
| | 45.7 ± 11.1 | 63.9 ± 18.7 | 0.001 |
| | 494 ± 127 | 689 ± 157 | 0.002 |
| | 7 ± 3 | 9 ± 2 | 0.102 |
| | 5.7 ± 1.4 | 7.4 ± 1.8 | 0.002 |
| | 98 ± 42 | 91 ± 31 | 0.573 |
| | 64 ± 12 | 50 ± 8 | <0.001 |
| VT REST (L) | 0.57 ± 0.16 | 0.70 ± 0.29 | 0.089 |
| VT PEAK (L) | 1.37 ± 0.44 | 1.72 ± 0.37 | 0.011 |
| | 0.57 ± 0.14 | 0.60 ± 0.09 | 0.39 |
Data are expressed as the mean ± standard deviation. Abbreviatures: 6MWD: six-minute walk distance; SpO2: oxyhemoglobin saturation by pulse oximetry; WR: work rate; : oxygen uptake; GET: gas exchange threshold; HR: heart rate; : minute ventilation; : carbon dioxide output; VT: tidal volume; MVV: maximal voluntary ventilation.
‡ Evaluated in 29 patients.
Fig 1A) Six-minute walking distance (6MWD) and B) oxygen consumption at the peak of cardiopulmonary exercise test () as a function of maximum inspiratory pressure (MIP). Horizontal gray lines represent median of variables.
Fig 2Borg dyspnea ratings as a function of work rate (WR) () (. Panel C and D shows tidal volume (VT) /inspiratory time (TI) ratio–a crude index of neural drive–and respiratory frequency (f) as a function of (*p < 0.05).